PDE-5-i were shown to reverse MDSC function in cancer patients and augment anti-tumor immunity by inhibiting the degradation of cyclic guanosine monophosphate (cGMP), leading to reduction in ARG1 and iNOS expression (Serafini et al., 2006; Noonan et al., 2014). The gene discussed is ARG1; the disease is neoplasm.